1st University Department of Ophthalmology, AHEPA Hospital, Glaucoma Unit, Thessaloniki, Greece.
Expert Opin Pharmacother. 2013 Sep;14(13):1815-27. doi: 10.1517/14656566.2013.813482. Epub 2013 Jun 28.
Glaucoma is a multifactorial optic neuropathy that can lead to progressive and irreversible loss of vision. Today there are > 60 million glaucoma patients worldwide, and this figure is rising due to aging. The aim of glaucoma therapy is to maintain the patient's visual function and quality of life by means of intraocular pressure (IOP) reduction, which currently constitutes the only evidence-based approach.
Briefly discussed are selected, recent evidence on antiglaucoma fixed combinations. Then the efficacy and safety of the latanoprost/timolol fixed combination is comprehensively reviewed.
The latanoprost/timolol fixed combination can be a helpful stepwise therapeutic option in patients whose IOP is insufficiently controlled with monotherapy options. Future research is needed to better delineate the role and value of this medication in glaucoma therapy.
青光眼是一种多因素的视神经病变，可导致视力进行性和不可逆转的丧失。目前全球有超过 6000 万青光眼患者，由于人口老龄化，这一数字还在不断上升。青光眼治疗的目的是通过降低眼内压（IOP）来维持患者的视觉功能和生活质量，这是目前唯一基于证据的方法。
简要讨论了最近关于抗青光眼固定组合的证据。然后全面回顾了拉坦前列素/噻吗洛尔固定组合的疗效和安全性。
对于那些仅用单药治疗方案无法有效控制眼压的患者，拉坦前列素/噻吗洛尔固定组合可能是一种有益的阶梯式治疗选择。需要进一步的研究来更好地阐明这种药物在青光眼治疗中的作用和价值。
